Optimum chemotherapy in the management of metastatic pancreatic cancer
Optimum chemotherapy in the management of metastatic pancreatic cancer
复制标题
DOI：
10.3748/wjg.v20.i9.2352
复制
发表时间：
2014-03-07
影响因子：
4.3
通讯作者：
Nasr, Dolly
中科院分区：
文献类型：
--
作者：
Ghosn, Marwan;Kourie, Hampig Raphael;Nasr, Dolly
胰腺癌是最具破坏性的实体肿瘤之一，也是最难治疗的肿瘤之一。转移性胰腺癌（MPC）的治疗是全身性的，基于化疗或最佳支持治疗，这取决于患者的表现状态。两种化疗方案在治疗MPC方面产生了实质性的益处：1997年的吉西他滨；和2011年的FOLFIRIONOX。FOLFIRINOX改善了MPC的自然病程，总生存期（OS）为11.1个月。Nab -紫杉醇联合吉西他滨是一种新批准的MPC治疗方案，中位OS为8.6个月。尽管进行了多次试验，但这种靶向治疗在MPC治疗中并不有效。许多靶向增殖和生存途径、免疫应答、癌胎信号和表观遗传变化的新分子目前正处于发育阶段。和。治疗MPC的试验，取得了许多有希望的结果。（三）2014年百世登出版集团有限公司版权所有。
Pancreatic cancer is one of the most devastating solid tumors, and it remains one of the most difficult to treat. The treatment of metastatic pancreatic cancer (MPC) is systemic, based on chemotherapy or best supportive care, depending on the performance status of the patient. Two chemotherapeutical regimens have produced substantial benefits in the treatment of MPC: gemcitabine in 1997; and FOLFIRIONOX in 2011. FOLFIRINOX improved the natural history of MPC, with overall survival (OS) of 11.1 mo. Nab -paclitaxel associated with gemcitabine is a newly approved regimen for MPC, with a median OS of 8.6 mo. Despite multiple trials, this targeted therapy was not efficient in the treatment of MPC. Many new molecules targeting the proliferation and survival pathways, immune response, oncofetal signaling and the epigenetic changes are currently undergoing phase. and. trials for the treatment of MPC, with many promising results. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.